Payers aim to rein in specialty drug spending

Wall Street Journal (subscription required), March 21, 2008
Due to the rising expenditures for cancer drugs and other high-priced medicines, employers, health plans and pharmacy-benefit managers are increasing efforts to rein in spending. To curb use, payers are pushing for legislation to permit the sale of cheaper versions of biotech drugs. They are also reinforcing rules about trying cheaper therapies first and early certification of patients' prescriptions. Some are even suggesting paying drug companies based on how well a drug works, rather than how much is used.

MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2015 a division of BLR All rights reserved.